Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Morphometric and Functional Changes of Rat Pituitary Somatotropes and Lactotropes after Central Administration of Somatostatin

Milošević V.a · Brkić B.b · Velkovski S.D.c · Sekulić M.a · Lovren M.a · Starčević V.c · Severs W.B.d

Author affiliations

a Institute for Biological Research ‘Siniša Stanković, b Clinical Centre ‘Dr. Dragiša Mišović’, and c Institute of Physiology School of Medicine, University of Belgrade, Yugoslavia, and d Department of Pharmacology, Pennsylvania State University, College of Medicine, Hershey, Pa., USA

Related Articles for ""

Pharmacology 1998;57:28–34

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: June 26, 1998
Issue release date: July 1998

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Abstract

This study examined effects of intracerebroventricularly (i.c.v.) administered somatostatin (SRIH-14 and SRIH-28) on growth and function of pituitary somatotropes (GH cells) and lactotropes (PRL cells). Male rats received three i.c.v. injections (1 µg/5 µl) of SRIH-14 or SRIH-28 every second day. Blood samples were collected for hormone assays and pituitaries were removed for histological and morphometric evaluation 5 days after the last i.c.v. treatment. Compared to control animals, SRIH treatment decreased (p < 0.05) pituitary weight and all morphometric measurements obtained in GH and PRL cells. Concentrations of serum growth hormone (GH) and prolactin (PRL) in both SRIH-treated groups were also lower (p < 0.05) than in control rats. These findings suggest that centrally administered somatostatin is specifically involved in the control of growth and secretory activity of GH and PRL cells. Thus, pharmacological manipulation of SRIH receptors reached from cerebrospinal fluid may alter systemic effects of GH and PRL.


References

  1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormones. Science 1973;179:77–79.
  2. Reichlin S: Somatostatin. N Engl J Med 1983;309:1495–1501, 1556–1563.
  3. Raulf F, Pérez J, Hoyer D, Bruns C: Differential expression of five somatostatin receptor subtypes, SSTR1–5, in the CNS and peripheral tissue. Digestion 1994;55(suppl 3):46–53.
  4. Epelbaum J: Somatostatin in the central nervous system, physiological and pathological modifications. Prog Neurobiol 1986;27:63–100.
  5. Epelbaum J, Bertherat J, Prevost G, Kordon C, Meyerhof W, Wulfsen I, Richter D, Plouin P-F: Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J Clin Endocrinol Metab 1995;80:1837–1844.
    External Resources
  6. Wehrenberg WB, Ling N, Brazeau P, Esch F, Böhlen P, Baird A, Ying S, Guillemin R: Somatostatin, growth hormone-releasing factor, stimulates secretion of growth hormone in anesthetized rats. Biochem Biophys Res Commun 1982;109:382–387.
    External Resources
  7. Epelbaum J, Doumaud P, Fodor M, Viollet C: The neurobiology of somatostatin. Crit Rev Neurobiol 1994;8:25–44.
  8. Patel YC: General aspects of the biology and function of somatostatin. Basic Clin Aspects Neurosci 1992;4:1–16.
  9. Gillies G: Somatostatin: The neuroendocrine story. Trends Pharmacol Sci 1997;18:87–95.
    External Resources
  10. Starčević VP, Morrow BA, Farner LA, Keil LC, Severs WB: Long-term recording of cerebrospinal fluid pressure in freely behaving rats. Brain Res 1988;462:112–117.
  11. Sternberger LA, Hardy PHJ, Cuculius JJ, Meyer HG: The unlabelled antibody enzyme method of immunohistochemistry. Preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem 1970;18:315–333.
    External Resources
  12. Weibel ER: Stereological Methods. 1. Practical Methods for Biological Morphometry. New York, Academic Press, 1979, pp 1–415.
  13. Weibel ER, Gomez DM: A principle for counting tissue structures on random sections. J Appl Physiol 1962;17:343–348.
  14. Meyerhof W, Wulfsen I, Schönrock C, Fehr S, Richter D: Molecular cloning of a somatostatin-28 receptor and comparison of its expression pattern with that of a somatostatin-14 receptor in rat brain. Proc Natl Acad Sci USA 1992;89:10267–10271.
    External Resources
  15. Epelbaum J, Enjalbert A, Krantic S, Musset F, Bertrand P, Rasolonjanahary R, Shu C, Kordon C: Somatostatin receptors on pituitary somatotropes, thyrotropes and lactotropes: Pharmacological evicence for loose coupling to adenylate cyclase. Endocrinology 1987;121:2177–2185.
    External Resources
  16. Chen C, Clarke IJ: Ion channels in the regulation of growth hormone secretion from somatotropes by somatostatin. Growth Regul 1992;2:167–174.
  17. Chen C, Vincent J-D, Clarke IJ: Ion channels and the signal transduction pathways in the regulation of growth hormone secretion. Trends Endocrinol Metab 1994;5:227–233.
  18. Blanchard MM, Goodyer CG, Charrier J, Barenton B: In vitro regulation of growth hormone (GH) release from bovine pituitary cells during fetal and neonatal development: Effects of GH-releasing factor, somatostatin and insulin- like growth factor I. Endocrinology 1988;122:2114–2120.
  19. Tannenbaum GS: Somatostatin as a physiological regulator of pulsatile growth hormone secretion. Horm Res 1988;29:70–74.
    External Resources
  20. Shimada O, Tosaka-Shimada H: Morphological analysis of growth hormone release from rat somatotropes into blood vessels by immunogold electron microscopy. Endocrinology 1989;125:2677–2682.
  21. Shimada O, Tosaka-Shimada H, Ishikawa H: Morphological effects of somatostatin on rat somatotropes previously activated by growth hormone-releasing factor. Cell Tissue Res 1990;261:219–229.
  22. Horvath E, Kovacs K: Morphology of adenohypophysial cells and pituitary adenomas; in Imura H (ed): The Pituitary Gland. New York, Raven Press, 1994, pp 29–62.
  23. Pantić V: Gonadal steroids as modulators of genetically programmed development of neuroendocrone cells involved in regulation of growth and reproduction. Bull Acad Serbe Sci Arts Classe Sci Nat 1990;32:47–66.
  24. Nikitovitch-Winer MB, Atkin J, Maley BE: Colocalization of prolactin and growth hormone within specific adenohypophyseal cells in male, female and lactating female rats. Endocrinology 1987;121:625–630.
  25. Sasaki F, Iwama Y: Sex difference in prolactin and growth hormone cells in mouse adenohypophysis: Stereological, morphometric and immunohistochemical studies by light and electron microscopy. Endocrinology 1988;123:905–912.
  26. Frawley LS: Mammosomatotropes: Current status and possible functions. Trends Endocrinol Metab 1989;1:31–34.
  27. Takashi S: Heterogeneity and development of somatotropes and mammotropes in the rat. Zool Sci 1992;9:901–924.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: June 26, 1998
Issue release date: July 1998

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.